Terminal Distributor of Dangerous Drugs License
A Terminal Distributor of Dangerous Drugs (TDDD) is a person (includes an individual; partnership; association; limited liability company; corporation; the state; any political subdivision of the state; and any district, department, or agency of the state or its political subdivisions) who is engaged in the sale of dangerous drugs at retail, or any person, other than a wholesale distributor or a pharmacist, who has possession, custody, or control of dangerous drugs for any purpose other than for that person’s own use and consumption, and includes pharmacies, hospitals, nursing homes, and laboratories and all other persons who procure dangerous drugs for sale or other distribution by or under the supervision of a pharmacist or licensed health professional authorized to prescribe drugs.
- As of April 1, 2017, all prescribers that possess compounded drugs or engage in the compounding of dangerous drugs (i.e. prescription drugs) must have a TDDD license (Ohio Revised Code 4729.541). More information on this provision can be found on the SOBP website.
- As of June 1, 2017, all locations, including those previously exempted, that possess controlled substances are required to obtain licensure as a category III TDDD. More information on this provision can be found on the SOBP website.
- Office-Based Opioid Treatment: Effective Tuesday, October 31, 2017, all locations that treat more than 30 individuals for opioid dependence or addiction using a controlled substance are required to obtain a TDDD license with an office-based opioid treatment classification. Please be advised that there are some exemptions to this requirement. More information on this provision can be found on the SOBP website.
- Applications for Licensure
- Compounding in Ohio (includes the legal definition of compounding)
- FAQ on Application Legal Questions
- Prescriber Compounding Rules for Hazardous Drugs
- TDDD License Exemptions
Additional Resource
Additional Information
- OAFP Signs on to Comment Letter Regarding Drug Distributor Rules (Weekly Family Medicine Update, March 27, 2018)
- OAFP Submits Comments to Pharmacy Board on Compounding Rules Draft (Weekly Family Medicine Update, March 27, 2018)
- Office-Based Opioid Treatment TDDD License Deadline Extended (Weekly Family Medicine Update, June 13, 2017)
- Pharmacy Board Releases New Guidance Documents on Recent TDDD License Changes (Weekly Family Medicine Update, March 7, 2017)
- Pharmacy Board Files Response on Compounding Rules with CSI (Weekly Family Medicine Update, August 30, 2016)
- Update on Pharmacy Compounding Rules (Weekly Family Medicine Update, August 16, 2016)
- Update on Pharmacy Compounding Rules (Weekly Family Medicine Update, August 9, 2016)
- OAFP Files Additional Comments on Compounding Rules (Weekly Family Medicine Update, August 2, 2016)
- Pharmacy Board Revises Proposed Compounding Rules (Weekly Family Medicine Update, July 26, 2016)
- OAFP Calls for Pharmacy Board to Indefinitely Suspend Compounding Rules (Weekly Family Medicine Update, July 12, 2016)
- Pharmacy Board Met June 6 to Consider Concerns Expressed About Compounding Rules (Weekly Family Medicine Update, June 7, 2016)
- Pharmacy Board to Revisit TDDD Licensure Rule; OAFP Outlines Concerns (Weekly Family Medicine Update, May 24, 2016)
- Pharmacy Board to Revisit TDDD Licensure Rule (Weekly Family Medicine Update, May 17, 2016)
- Update on TDDD Licensing Requirement (Weekly Family Medicine Update, May 10, 2016)
- Pharmacy Board Adopts New TDDD License Requirements for Possessing Compounded Drugs (Weekly Family Medicine Update, May 3, 2016)
- Board of Pharmacy Adopts New Rules on Drug Compounding by Prescribers (Weekly Family Medicine Update, March 8, 2016)